Dysregulation of ubiquitin homeostasis and beta-catenin signaling promote spinal muscular atrophy

Citation for published version:

Digital Object Identifier (DOI):
10.1172/JCI71318

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Journal of Clinical Investigation

Publisher Rights Statement:
Copyright © 2014 American Society for Clinical Investigation

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy

Thomas M. Wishart,1,2 Chantal A. Mutsaers,1,3 Markus Riessland,4 Michell M. Reimer,1,5 Gillian Hunter,1,3 Marie L. Hannam,5 Samantha L. Eaton,2 Heidi R. Fuller,7 Sarah L. Roche,1,3 Eilidh Somers,1,3 Robert Morse,8 Philip J. Young,8 Douglas J. Lamont,9 Matthias Hammerschmidt,10 Anagha Joshi,11 Peter Hohenstein,11 Glenn E. Morris,7 Simon H. Parson,1,12 Paul A. Skehel,1,3 Thomas Becker,1,5 Iain M. Robinson,6 Catherina G. Becker,1,5 Brunhilde Wirth,4 and Thomas H. Gillingwater1,3

1Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, United Kingdom. 2Division of Neurobiology, The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, United Kingdom. 3Centre for Integrative Physiology, University of Edinburgh, Edinburgh, United Kingdom. 4Institute of Human Genetics, Institute for Genetics and Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany. 5Centre for Neuroregeneration, University of Edinburgh, Edinburgh, United Kingdom. 6Peninsula College of Medicine and Dentistry (Universities of Exeter and Plymouth), John Bull Building, Research Way, Tamar Science Park, Plymouth, United Kingdom. 7Wolfson Centre for Inherited Neuromuscular Disease, RJAH Orthopaedic Hospital, Oswestry, United Kingdom, and Institute for Science and Technology in Medicine, Keele University, Keele, United Kingdom. 8Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, United Kingdom. 9Fingerprints Proteomics Facility, Dundee University, Dundee, United Kingdom. 10Institute of Developmental Biology, University of Cologne, Cologne, Germany. 11Division of Developmental Biology, The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, United Kingdom. 12Institute of Medical Sciences, School of Medicine and Dentistry, University of Aberdeen, Aberdeen, United Kingdom.

The autosomal recessive neurodegenerative disease spinal muscular atrophy (SMA) results from low levels of survival motor neuron (SMN) protein; however, it is unclear how reduced SMN promotes SMA development. Here, we determined that ubiquitin-dependent pathways regulate neuromuscular pathology in SMA. Using mouse models of SMA, we observed widespread perturbations in ubiquitin homeostasis, including reduced levels of ubiquitin-like modifier activating enzyme 1 (UBA1). SMN physically interacted with UBA1 in neurons, and disruption of Uba1 mRNA splicing was observed in the spinal cords of SMA mice exhibiting disease symptoms. Pharmacological or genetic suppression of UBA1 was sufficient to recapitulate an SMA-like neuromuscular pathology in zebrafish, suggesting that UBA1 directly contributes to disease pathogenesis. Dysregulation of UBA1 and subsequent ubiquitination pathways led to β-catenin accumulation, and pharmacological inhibition of β-catenin robustly ameliorated neuromuscular pathology in zebrafish, Drosophila, and mouse models of SMA. UBA1-associated disruption of β-catenin was restricted to the neuromuscular system in SMA mice; therefore, pharmacological inhibition of β-catenin in these animals failed to prevent systemic pathology in peripheral tissues and organs, indicating fundamental molecular differences between neuromuscular and systemic SMA pathology. Our data indicate that SMA-associated reduction of UBA1 contributes to neuromuscular pathogenesis through disruption of ubiquitin homeostasis and subsequent β-catenin signaling, highlighting ubiquitin homeostasis and β-catenin as potential therapeutic targets for SMA.

Introduction

Proximal spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality, with a carrier frequency of 1 in 35 in the population of mixed European descent and an incidence of approximately 1 in 6,000–10,000 live births (1, 2). This autosomal recessive neuro muscular disorder is most commonly caused by homozygous deletion of the survival motor neuron 1 (SMA) gene, leading to reduced levels of ubiquitously expressed full-length SMN protein (1, 3). SMA is primarily characterized by degeneration of lower motor neurons and atrophy of skeletal muscle (3, 4), with functional and structural disruption of synaptic connectivity at neuromuscular junctions (NMJ) and in the spinal cord occurring during the early stages of disease pathogenesis (5–9). However, recent studies have revealed that SMA, particularly in its most severe forms, is a multisystem disorder (10), with other regions of the nervous system also being affected (e.g., the hippocampus; ref. 11) as well as nonneuronal tissues and organs, including heart (12), vasculature (13), liver (14), pancreas (15), lung, and intestines (16). This suggests that SMN deficiency causes perturbations across a wide range of cells and tissues in SMA, albeit with motor neurons being the most vulnerable cell type.

Despite a clear understanding of the genetic causes of SMA, the mechanisms linking low levels of SMN to disease pathogenesis remain unclear. SMN protein is known to play key roles in several core canonical cellular pathways, including snRNP biogenesis and pre-mRNA splicing (3). However, attempts to link disruptions in RNA processing directly to SMA pathogenesis have proven controversial (17–20). The finding that mutations in genes encoding
proteins not directly involved in RNA processing can cause related
diseases (e.g., mutations in BICD2 cause congenital autosomal- 
dominant SMA, ref. 21; and mutations in ubiquitin-like modifier
activating enzyme 1 [UBA1] cause X-linked infantile SMA, ref. 22),
alongside reports linking SMN protein to actin dynamics (23, 24),
Phosphatase and tensin homolog–mediated (PTEN-mediated)
protein synthesis pathways (25), and translational regulation (26),
suggests that SMN may fulfill additional roles downstream from, or
outside of, RNA processing pathways in the nucleus and cell body of
neurons. The identification of key pathways downstream from SMN
that are critical for the regulation of neuromuscular and system-
wide pathology in SMA will be important for designing, testing, and
evaluating new therapeutic approaches for SMA patients.

The studies described here were initiated to identify key molecu-
lar pathways present in the neuronal cytoplasm and acting down-
stream of SMN that are responsible for regulating neuromuscular
and systemic pathology in SMA. Combining proteomic screens
with cellular and molecular approaches in mouse, Drosophila, and
zebrafish models, we reveal widespread disruption to ubiquitin
homeostasis in SMA, leading to perturbations in β-catenin signal-
ing pathways in the neuromuscular system.

Results

Widespread perturbations in ubiquitin homeostasis in animal models
of SMA. The initial aim of the study was to identify functional
molecular pathways modified downstream of SMN depletion
in SMA. In order to examine neuronal material that was bio-
logically relevant and yet free from contamination by nuclear and/or
myelin proteins (the abundance of which can hamper the sensitiv-
ity of proteomics screens), we initially performed unbiased iTRAQ
comparative proteomics on synapses isolated from the hippocam-
pus of presymptomatic (P1) “severe” SMA mice (Snn+/− SMN2+/#)
compared with littermate controls (Snn+/+ SMN2+/#). We chose
to use hippocampal synaptosomes for these experiments due to
the known susceptibility of the hippocampus in mouse models of
SMA (11), as well as the known susceptibility of synaptic compart-
ments of neurons in SMA during the early stages of disease (7, 8).
Biochemical analysis of isolated synaptic preparations from mice
confirmed the presence of SMN protein and its known interacting
proteins (e.g., gemin5) in the synaptic cytoplasm at CNS synapses
(Supplemental Figures 1 and 2; supplemental material available
online with this article; doi:10.1172/JCI71318DS1). SMN protein
was also present in synaptic boutons at the Drosophila NMJ (Sup-
lemental Figures 1 and 2), confirming the biological relevance of
using synaptic preparations for the initial proteomics screen.

The iTRAQ screen revealed robust disruption of the synaptic
proteinome in SMA mice, where 52 out of 150 (35%) unique pro-
teins identified had expression levels modified by more than 20%
in SMA mice (Supplemental Tables 1 and 2). Functional clustering
analyses, using IPA software (see Methods), linked these indi-
vidual protein changes to significant modifications in a range of
canonical functional pathways (Table 1). Interestingly, these analy-
yses highlighted significant disruption to protein ubiquitination
pathways in SMA mice, with decreased levels of UBA1 (Supple-
mental Figure 3A) and increased levels of ubiquitin carboxyter-
minal esterase L1 (UCHL1) (Table 1 and Supplemental Tables 1
and 2). Ubiquitination pathways, and UBA1 in particular, were of
interest in the context of SMA because mutations in the gene cod-
ing for human UBA1 (UBE1) are sufficient to cause a genetically
distinct form of the disease, known as X-linked infantile SMA (22).
Moreover, ubiquitination pathways are known to regulate axonal
and synaptic stability (27) as well as the stability and degradation
of the SMN protein itself (28–30).

To establish whether disruption of ubiquitin-dependent path-
ways was conserved across the range of cells and tissues present
in the neuromuscular system, UBA1 protein levels were examined
in preparations of spinal cord (Figure 1, A and B, and Supplement-
al Figure 3B) and skeletal muscle (Figure 1, A and C) from severe
SMA mice. UBA1 protein levels were reduced approximately 50%
in SMA mouse spinal cord (Figure 1B) and more than 60% in skel-
etal muscle (gastrocnemius; Figure 1C) at P5.

UBA1 regulates the first stages of an enzymatic cascade in which
ubiquitin molecules are ultimately conjugated to target proteins;
therefore, disruption of UBA1 (alongside concomitant changes
in other ubiquitin-related proteins such as UCHL1) would be
predicted to affect overall ubiquitin homeostasis. To determine
whether this occurred in SMA, we measured levels of ubiquitin
in the spinal cords from severe SMA mice. Levels of both monomeric
and multimeric ubiquitin were significantly decreased (Figure 1,
D–F). SMN-dependent perturbations in ubiquitin homeostasis
were also observed across other species and tissues, as a dramatic
redistribution of mono- and polyubiquitinated proteins was
observed in striated muscle from an established Drosophila
model of SMA (Figure 1G and ref. 31).

To determine the time course of UBA1 changes in SMA, we
examined UBA1 expression in “Taiwanese” SMA mice, which dis-
dplay a milder phenotype than severe SMA mice (mean survival of
∼11 days compared with ∼5–6 days; ref. 32). We examined UBA1
protein expression in motor neuron cell soma located in the ven-
tral horn of spinal cord at presymptomatic (P3) and early symp-
tomatic (P7) stages of disease (Figure 1, H–J). In control mice,
UBA1 was almost exclusively localized to the neuronal cytoplasm
at P3, before undergoing a dramatic subcellular relocation to
the nucleus by P7 (Figure 1, H and I). There was no overt differ-
cence in UBA1 localization in SMA mice at P3. However, at P7, we
noted an almost complete absence of UBA1 from the motor neu-

<table>
<thead>
<tr>
<th>Pathway</th>
<th>P value</th>
<th>Individual proteins (&gt;20% changed in SMA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxidative phosphorylation</td>
<td>1.61 × 10^{−07}</td>
<td>ATP5A1, ATP5F1, ATP6V1A, COX5A, CYC1, PPA1</td>
</tr>
<tr>
<td>Protein ubiquitination</td>
<td>8.59 × 10^{−06}</td>
<td>HSP90AA1, HSP90AB1, HSP9A, HSPD1, PSMD2, UBA1, UCHL1</td>
</tr>
<tr>
<td>Glycolysis/gluconeogenesis</td>
<td>1.14 × 10^{−04}</td>
<td>ALDOA, PGAM1, PKG1, PKM2</td>
</tr>
<tr>
<td>Purine metabolism</td>
<td>1.15 × 10^{−04}</td>
<td>ATP1B1, ATP5A1, ATP5F1, HSP90AA1, HSPD1, PKM2</td>
</tr>
<tr>
<td>PI3K/AKT signaling</td>
<td>3.64 × 10^{−04}</td>
<td>CTNNB1, HSP90AA1, HSP90AB1, YWHAG</td>
</tr>
</tbody>
</table>

The iTRAQ screen revealed robust disruption of the synaptic
<table>
<thead>
<tr>
<th>Pathway</th>
<th>P value</th>
<th>Individual proteins (&gt;20% changed in SMA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxidative phosphorylation</td>
<td>1.61 × 10^{−07}</td>
<td>ATP5A1, ATP5F1, ATP6V1A, COX5A, CYC1, PPA1</td>
</tr>
<tr>
<td>Protein ubiquitination</td>
<td>8.59 × 10^{−06}</td>
<td>HSP90AA1, HSP90AB1, HSP9A, HSPD1, PSMD2, UBA1, UCHL1</td>
</tr>
<tr>
<td>Glycolysis/gluconeogenesis</td>
<td>1.14 × 10^{−04}</td>
<td>ALDOA, PGAM1, PKG1, PKM2</td>
</tr>
<tr>
<td>Purine metabolism</td>
<td>1.15 × 10^{−04}</td>
<td>ATP1B1, ATP5A1, ATP5F1, HSP90AA1, HSPD1, PKM2</td>
</tr>
<tr>
<td>PI3K/AKT signaling</td>
<td>3.64 × 10^{−04}</td>
<td>CTNNB1, HSP90AA1, HSP90AB1, YWHAG</td>
</tr>
</tbody>
</table>
Figure 1

Perturbations in UBA1 levels and ubiquitin homeostasis in mouse and Drosophila models of SMA. (A–C) Significant reduction in levels of UBA1 protein in spinal cord and skeletal muscle from severe SMA mice at P5 compared with littermate controls (con), quantified using fluorescent Western blot (n = 3 mice/genotype; unpaired 2-tailed t test). (D–F) Reduced levels of both monomeric and multimeric ubiquitin in the spinal cord of Taiwanese SMA mice at P10 (tubulin: loading control; n = 3 mice/genotype). (G) Representative confocal micrographs of striated muscle from WT and SMA Drosophila larvae immunolabeled with an antibody that recognizes mono- and polyubiquitinated proteins (green). Diffuse staining in muscle and muscle nuclei (stained with Hoechst, blue) of WT flies contrasted with a distinct lack of nuclear staining and increased perinuclear staining in SMA flies. Each panel in G is 75 μm in length. (H and I) UBA1 (green) and NeuN (red) immunolabeling of motor neurons from Taiwanese SMA and littermate control mouse spinal cords at P3 (H) and P7 (I). Note how UBA1 was predominantly cytoplasmic at P3 but nuclear at P7. Scale bars: 10 μm. (J) Significant increase in the ratio of nuclear to cytoplasmic UBA1 in SMA motor neurons at P7 compared with littermate controls (n = 24 motor neurons per genotype). (K) UBA1 levels in whole spinal cord of Taiwanese SMA mice remained unchanged at P3 and P7, but were significantly reduced by P10 (n > 3 mice per time point/genotype; ANOVA with Tukey’s post-hoc test). (L) Levels of UBA1 in skeletal muscle were significantly reduced at an early symptomatic age (P7) in Taiwanese SMA mice (n = 4 mice per genotype). *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 2

UBA1 physically interacts with SMN protein in vivo, and Uba1 splicing is dysregulated at late symptomatic time points in SMA mouse spinal cord. (A) No change in levels of Uba1 mRNA (or a control mRNA, Fth1; similar control data using Mapt not shown) in the spinal cord of P5 severe SMA mice, quantified using qPCR (n = 3 mice per genotype; ANOVA with Tukey’s post hoc test). (B) Representative fluorescent Western blots for SMN (left lane) and UBA1 (right lane) from co-IP experiments on spinal cord extracts from WT mice, using SMN-bound beads, demonstrating that UBA1 physically interacts with SMN in vivo. (C) Graphic overview of the exon structure of Uba1. Two Uba1 splice variants are generated with unique first exons. The position of primers used to amplify each splice variant is highlighted. Note that the coding sequence of Uba1 starts in exon 2. (D–F) Bar charts showing relative expression levels of Uba1a and Uba1b, as well as the ratio of Uba1a to Uba1b, in SMA (Taiwanese) and control spinal cord at P3 (D; presymptomatic), P7 (E; early symptomatic), and P11 (late-symptomatic) (n = 3 mice per genotype, 3 independent amplifications per sample; 2-tailed, unpaired t tests). Uba1 splicing was significantly dysregulated in the late-symptomatic mice. **P < 0.01; ***P < 0.001.
ron cytoplasm in SMA mice, when low levels persisted in littermate control mice (Figure 1I). Quantification of the ratio of nuclear/cytoplasmic UBA1 levels in SMA mice revealed a significant reduction in the cytoplasm compared with controls (Figure 1J). Thus, redistribution of UBA1 occurring during the early postnatal period was perturbed in SMA mice at early symptomatic stages of the disease. Interestingly, quantification of total UBA1 levels in spinal cord did not reveal a significant reduction in SMA mice until late-symptomatic stages (P10; Figure 1K), suggesting that subtle changes in the subcellular distribution of UBA1 were perturbed in motor neurons in advance of a widespread reduction in protein levels throughout the spinal cord. Comparable examination of UBA1 levels in whole muscle showed a significant loss by P7 in SMA (Figure 1L), suggesting that muscle may be more severely affected than spinal cord.

**SMN-Uba1 interactions and dysregulation of Uba1 splicing in SMA.** To investigate potential pathways through which UBA1 and ubiquitin homeostasis are targeted in SMA, we first asked whether changes were occurring due to reduced expression of Uba1 mRNA. As mRNA levels for Uba1 remained unchanged in the spinal cords of SMA mice (Figure 2A), it was unlikely that UBA1 protein levels were reduced as a result of global deficiencies in transcription of Uba1 mRNA. Given that SMN protein interacts with other proteins in vitro, including members of the ubiquitin-proteasome sys-

---

**Figure 3**

Genetic and pharmacological suppression of *uba1* in zebrafish leads to dose-dependent motor axon pathology. (A) Representative fluorescence micrographs of motor axons growing out from the spinal cord in a control zebrafish 34 hours after fertilization, and in animals injected with either 4 ng or 6 ng of a MO suppressing *uba1* levels (see Supplemental Figure 4). (B) Representative higher-magnification confocal micrographs showing abnormal sprouts and axonal extensions in motor axons from MO-treated zebrafish. Scale bars: 50 μm. (C) Dose-dependent increase in the occurrence of abnormal branching in MO-treated zebrafish (Kruskal-Wallis test with Dunn’s post hoc test; uninjected, *n* = 310 motor neurons, 4 ng, *n* = 360, *n* = 36 animals; 6 ng, *n* = 360, *n* = 36 animals). Only motor axons with modest (type 2; see Supplemental Figure 4) or severely abnormal branching (type 3; see Supplemental Figure 4) were quantified as having abnormal branching. (D) Representative confocal micrographs showing perturbations in motor axon morphology in Tg(hb9:gfp) zebrafish embryos treated with 50 μM of the UBA1 inhibitor UBEI-41. Note the presence of a “double-exit” motor axon (right hand side of image) in the UBEI-41 example, with the axon branch emerging on the right side of the pair showing stunted outgrowth. Scale bars: 100 μm; 30 μm (B, D). (E) Levels of abnormal motor axon branching and axon outgrowth in UBEI-41–treated zebrafish. Note the dose-dependent increase of numbers of aberrant motor axons in the UBEI-41 group compared with DMSO controls (10 μM UBEI-41 *n* = 258 nerves, *n* = 11 animals; 50 μM UBEI-41 *n* = 280 nerves *n* = 12 animals; Kruskal-Wallis test with Dunn’s post hoc test). ***P < 0.001.
the fact that UCHL1 (29, 30), we next wanted to determine whether SMN could be influencing UBA1 levels as a result of direct physical interactions in vivo. We therefore performed communoprecipitation (co-IP) experiments on spinal cord extracts from WT mice, using anti-SMN beads. Immunoblotting on the bound extract with antibodies against UBA1 revealed that UBA1 and SMN physically interact in the neuronal cytoplasm in vivo (Figure 2B).

Several recent studies have also implicated SMN in the regulation of splicing; therefore, we next analyzed splicing patterns for Uba1 in the spinal cords of Taiwanese SMA mice at presymptomatic (P3), early symptomatic (P7), and late-symptomatic (P10) time points (Figure 2, C–F). Two Uba1 splice variants are generated with unique first exons Uba1a and Uba1b (Figure 2C). Quantification of relative expression levels of Uba1a and Uba1b in SMA and control spinal cords at P3 and P7 showed no significant differences between the genotypes (Figure 2, D and E). In contrast, there was a significant reduction in relative expression levels of Uba1a (but not Uba1b) and a significant alteration in the ratio of Uba1a to Uba1b in SMA mice at P10 (Figure 2F). Thus, dysregulation of Uba1 splicing may contribute to the alterations in UBA1 protein levels observed in SMA, with the disruption in splicing in spinal cord temporally correlating with the reduction in UBA1 protein levels in spinal cord (see Figure 1K). Taken together with data showing UBA1 subcellular redistribution and UBA1-SMN interaction, these findings suggest that SMN-dependent regulation of UBA1 and its disruption in SMA is a complex process, with combinatorial effects of disruption to multiple regulatory pathways likely to be responsible.

Suppression of UBA1 is sufficient to induce motor neuron pathology in vivo. Although suppression of UBA1 and disruption of ubiquitin homeostasis were robust correlates of neuromuscular pathology in SMA, it remained unclear whether these changes directly contributed to disease pathogenesis. To examine this possibility, we designed experiments to suppress uba1 in zebrafish, an accessible model system to assess the effects of genetic manipulations on motor neuron stability (23, 33). Uba1 expression was targeted using an antisense Morpholino oligonucleotide (MO) designed against the translational start codon of the uba1 gene. Embryos were injected with either 4 ng or 6 ng of MO and examined 34 hours after fertilization. Levels of UBA1 protein were robustly reduced in fish treated at both doses (Supplemental Figure 4A). Suppression of uba1 using MO had no effect on the gross development of motor neurons in the spinal cord (Figure 3A). However, uba1 suppression did lead to a profound, dose-dependent disruption of motor axon outgrowth and branching. Whereas the vast majority of axons in control animals showed a simple, unbranched morphology, axons in both 4 ng and 6 ng MO–injected animals revealed grossly abnormal branching patterns (Figure 3, A and B). The percentage of motor axons with branching abnormalities (see Supplemental Figure 4B) increased from less than 5% in controls to approximately 50% in 4 ng MO animals and approximately 75% in 6 ng MO animals (Figure 3C). Importantly, these findings phenocopied branching defects previously reported in zebrafish models of SMA (23, 33).

To confirm these findings using pharmacological suppression of UBA1, we treated zebrafish with UBEI-41, a cell-permeable pharmacological UBA1 inhibitor (34). Inhibition of UBA1 revealed a similar, dose-dependent disruption of motor axon branching (Figure 3, D and E). At a dose of 10 μM UBEI-41, the majority of motor nerve abnormalities were due to aberrant axonal branching (data not shown). At 50 μM, however, approximately half of the motor nerve abnormalities observed (47.2%) were a result of aberrant nerve branching, with the remaining motor nerves revealing a more severe phenotype: truncated or missing motor axons (Figure 3D). Once again, these pathological events phenocopied motor axon defects observed in zebrafish models of SMA (23, 33). Thus, suppression of uba1 was sufficient to phenocopy SMA-like motor neuron pathology in vivo. In addition to the observed motor axon defects, uba1 suppression led to body axis defects in zebrafish, both following UBEI-41 treatment and following MO treatment (data not shown). However, the viability of the fish was not compromised, as there was not a significant increase in the number of fish dying after uba1 suppression.

SMN-dependent suppression of UBA1 leads to accumulation of β-catenin. Given that UBA1 is a key component of ubiquitination pathways through which substrate proteins are “tagged” for targeting to the proteasome, we therefore wanted to identify specific substrate proteins affected as a downstream consequence of the disruption to ubiquitin homeostasis in SMA. Perturbations in ubiquitin pathways are often associated with a failure to degrade target proteins, resulting in a characteristic accumulation within the cell. Reexamination of our original proteomics data set revealed that β-catenin levels were robustly increased, by more than 400%, in SMA mice (Table 1 and Supplemental Tables 1 and 2). Examination of β-catenin levels in freshly prepared synaptosomes from control (Smn+/+ SMN2tg/tg) or SMN-dependent suppression of UBA1 leads to accumulation of β-catenin (Figure 4A). β-catenin levels were also significantly increased in the spinal cords of Taiwanese SMA mice (Figure 4B and Supplemental Figure 6). Alongside changes in β-catenin levels, levels of stabilized β-catenin (ABC) were reduced in the spinal cord (Figure 4C and Supplemental Figure 5), and levels of transcription factor 4 (TCF-4), a key β-catenin–interacting protein required for activation of downstream response genes (35), were also significantly reduced (Figure 4D and Supplemental Figure 5). Importantly, β-catenin protein levels in muscle biopsy samples from SMA patients suggested that elevated levels were also a major feature of neuromuscular pathology in human patients (Figure 4I).

To confirm that increased levels of β-catenin were occurring downstream of perturbations in UBA1, we examined global β-catenin levels in zebrafish treated with 4 ng or 6 ng MO against uba1. β-Catenin levels were increased in a dose-dependent manner, reaching approximately 250% of control levels in zebrafish treated with 6 ng MO against uba1 (Figure 4E). To further confirm a link between UBA1 levels and the regulation of β-catenin in neurons, cultures of primary hippocampal neurons and NSC-34 motor neuron–like cells (36) were exposed to the UBA1 inhibitor UBEI-41 for 2 hours. UBEI-41 treatment led to a rapid and significant increase in levels of β-catenin in hippocampal neurons (∼50%; Figure 4F), with an even more robust increase in β-catenin levels observed in NSC-34 cells (∼90%; Figure 4F), suggesting that motor neurons were particularly susceptible to suppression of UBA1. To establish whether increased levels of β-catenin protein led to a corresponding increase in β-catenin signaling activity, we performed luciferase activity reporter experiments. β-Catenin activity was significantly increased in NSC-34 cells treated with UBEI-41 for 2 hours (Figure 4G). In order to ascertain whether such changes in β-catenin signaling activity could explain changes...
**Figure 4**

β-Catenin is a downstream target of UBA1 and accumulates in SMA. (A) β-Catenin and SMN protein in spinal cord of severe SMA, heterozygous (Het), and littermate (con) mice at P5 (tubulin: loading control). (B–D) β-Catenin was increased in P10 Taiwanese SMA mouse spinal cord (n = 3 control mice, n = 4 SMA; unpaired 2-tailed t test), whereas stabilized β-catenin (ABC; C) and TCF-4, a β-catenin interacting protein required for activation (D), were both reduced (n = 3 CON, n = 3 SMA). (E) Increased β-catenin protein in zebrafish injected with 4 ng or 6 ng of a uba1 MO 48 hours after fertilization. (F) Increased β-catenin in rat hippocampal neurons and a motor neuron cell line (NSC-34) treated with 50 μM UBEI-41 (ANOVA with Tukey's post-hoc test; n = 12 coverslips DMSO, n = 15 UBEI-41 hippocampal; n = 19 DMSO, n = 18 UBEI-41 NSC-34). (G) Increased β-catenin signaling activity in NSC-34 cells treated with 50 μM UBEI-41 measured with a luciferase reporter construct (n = 3 coverslips per treatment). (H) The majority of proteins modified in SMA synapses (66 out of 115 analyzed; see Supplemental Tables 1 and 2) are known β-catenin target genes identified by ChIP-Seq analyses. (I) Increased β-catenin protein in muscle biopsies from 3 human SMA patients (pooled data on right of dotted line). (J) Western blots for β-catenin (left panel; green) and ubiquitin (right panel; red) from co-IP experiments on synaptic extracts from 2 WT mice (L, ladder; M1, mouse 1; M2, mouse 2). Immunoblotting on the bound extract revealed the presence of ubiquitinated β-catenin (upper arrow). *P < 0.05; **P < 0.01; ***P < 0.001.
in levels of other proteins found to be altered in SMA synaptosomes, we compared our proteomics data set to published β-catenin ChIP-Seq data revealing potential downstream targets of β-catenin (37). This analysis revealed that the majority of proteins modified in SMA synapses (66 out of 115 analyzed) were present in the ChIP-seq data (Figure 4H), indicative of them being putative β-catenin targets.

β-catenin is a known target of the ubiquitin-proteasome system (38), but we wanted to confirm that the ubiquitin was being ubiquitinated in neurons. We therefore performed IP experiments on protein isolated from synaptosomes generated from WT mice (as in our initial proteomics screen, where increased levels of β-catenin were identified) using either β-catenin beads or pan-ubiquitin beads. Western blotting with antibodies against β-catenin and ubiquitin demonstrated that ubiquitinated forms of β-catenin were present in neurons and their synaptic compartments (Figure 4J).

**Inhibition of β-catenin signaling reverses UBA1-dependent destabilization of motor neurons.** To test whether the UBA1-dependent effects on motor nerve branching we observed previously were mediated by downstream effects on β-catenin signaling pathways, we exposed zebrafish embryos treated with the UBA1 inhibitor UBEI-41 to quercetin, a plant-derived flavonoid that robustly inhibits β-catenin signaling pathways by disrupting transcriptional activity of the β-catenin-Tcf complex (39–41). Treatment of fish with motor neuron defects resulting from the addition of 50 µM UBEI-41 with 25 µM or 50 µM quercetin revealed a dose-dependent rescue of the motor axon branching phenotype (Figure 5, A and B). Strikingly, in the fish treated with 50 µM quercetin, the number of abnormal motor nerves was reduced to that observed in control fish not exposed to the UBA1 inhibitor. Treatment with 50 µM quercetin also ameliorated motor axon branching defects in zebrafish treated with MO against uba1 (data not shown). Thus, motor nerve abnormalities induced by inhibition of uba1 in zebrafish were fully rescued by simultaneous inhibition of β-catenin signaling. In addition to the motor nerve disruptions observed, we noted that exposure to UBEI-41 caused dose-dependent alteration of the gross morphology of zebrafish embryos, manifesting as a bent body axis (Figure 5C). These deficits were also corrected by treatment with quercetin (Figure 5C).

**Inhibition of β-catenin signaling ameliorates neuromuscular pathology in zebrafish and Drosophila models of SMA.** Given that pharmacological inhibition of β-catenin signaling with quercetin was sufficient to block motor axon defects resulting from targeting of UBA1, we next wanted to know whether pharmacological inhibition of β-catenin signaling would have similar beneficial effects on neuromuscular pathology in animal models of SMA. Treatment with 50 µM quercetin robustly and significantly reduced the incidence of both truncated motor axons and motor axon branching defects in SMA zebrafish (33), reducing levels of motor axon pathology back to those observed in healthy control animals (Figure 6, A–C). Similarly, quercetin treatment reversed morphological defects associated with the NMJ in a dose-dependent manner in an established Drosophila model of SMA (31), rescuing both synaptic bouton size and bouton density in the treated SMA flies (Figure 6, D–F). Thus, pharmacological inhibition of β-catenin signaling with quercetin ameliorated key markers of neuromuscular pathology in both invertebrate and vertebrate models of SMA.

**Inhibition of β-catenin signaling ameliorates neuromuscular pathology, but not systemic pathology in SMA mice.** Finally, we wanted to establish whether pharmacological inhibition of β-catenin signaling with quercetin could have a similar effect on disease phenotype in SMA mice. Taiwanese SMA mice and littermate controls were treated with 10 mg/kg quercetin daily (i.p. injection) from birth. A parallel group of mice received injections of DMSO vehicle only. Treatment with 10 mg/kg quercetin was well tolerated by healthy littermate controls. This phenotype was rescued by quercetin treatment (Figure 5C). Representative confocal micrographs showing 3 segments of Tg(hb9:grnp) zebrafish embryos from the trunk region. Note the severe branching phenotype of the motor nerves in the UBEI-41–treated animal. This phenotype was rescued by quercetin treatment. Scale bar: 30 µm. (B) Dose-dependent increase in numbers of aberrant motor axons in the UBEI-41–treated group compared with DMSO controls. This phenotype was rescued by quercetin treatment in a dose-dependent manner (DMSO controls: n = 331 nerves, n = 14 animals; 10 µM UBEI-41: n = 258, n = 11; 50 µM UBEI-41 n = 280, n = 12; 50 µM UBEI-41 + 25 µM quercetin: n = 143, n = 6; 50 µM UBEI-41 + 50 µM quercetin: n = 168, n = 7; Kruskal-Wallis test with Dunn’s post hoc test). (C) Representative overview images showing body axis defects in zebrafish embryos after UBEI-41 treatment compared with DMSO controls. Note the rescue of this gross phenotype following application of 50 µM quercetin. ***P < 0.001.
Thus, as we previously observed in zebrafish and Drosophila models, pharmacological inhibition of β-catenin signaling with quercetin ameliorates neuromuscular dysfunction and pathology in SMA mice. Quercetin-treated mice often appeared much healthier than their DMSO-treated counterparts at late symptomatic stages (Figure 7D), but treatment with quercetin did not increase survival (Figure 7I) or average body weight (Supplemental Figure 6). Examination of quercetin-treated mice postmortem revealed the presence of widespread gross organ defects previously reported in SMA mice (Figure 7J), where systemic pathology is known to target organs including the heart and liver (10, 14, 16). In order to examine the possible causes of this failure to ameliorate nonneuromuscular, systemic pathology (even when quercetin was administered systemically via i.p. injection), we quantified UBA1 and β-catenin levels in the heart and liver from late-symptomatic Taiwanese SMA mice and littermate controls. Levels of UBA1 in the heart and liver were reduced in SMA mice to a level similar to that observed in spinal cord (Figure 7K). Surprisingly, however, β-catenin levels were not significantly modified in the heart and liver (Figure 7H). Thus, perturbations in β-catenin signaling pathways occurring downstream of disrupted ubiquitin homeostasis were restricted to the neuromuscular system and were not repeated in nonneuromuscular organs. This suggests that distinct mechanisms drive pathology in the neuromuscular system compared with other tissue and organ systems in SMA and may explain, at least in part, why pharmacological inhibition of β-catenin selectively ameliorated neuromuscular pathology in SMA mice.

**Discussion**

The studies described here were initiated to identify novel regulators of neuromuscular pathology in SMA. Using rodent, Drosophila, and zebrafish SMA models, we have revealed an important role for ubiquitin homeostasis, mediated largely via modifications in levels of UBA1. Suppression of UBA1 in SMA is likely to result from a complex series of events, including disruptions in both splicing of Uba1 mRNA and physical interactions between SMN and UBA1 protein in the cytoplasm. Experimental downregulation of UBA1 expression was sufficient to generate motor neuron pathology in vivo, phenocopying the severe axonal defects (Figure 7, G and H). Thus, as we previously observed in zebrafish and Drosophila models, pharmacological inhibition of β-catenin signaling with quercetin ameliorates neuromuscular dysfunction and pathology in SMA mice.
Figure 7
Pharmacological inhibition of β-catenin ameliorates neuromuscular, but not systemic, pathology in SMA mice. (A) Significant improvement on the righting test in early (P6) and late-symptomatic (P9) Taiwanese SMA mice (KO) treated with 10 mg/kg quercetin (Kruskal-Wallis test with Dunn's post hoc; P3, n = 30 tests Het; n = 27 KO; n = 21 KOQ; P6, n = 31, Het; n = 28 KO; n = 27 KOQ; P9, n = 32, Het; n = 27 KO; n = 36 KOQ). (B and C) Reduced motor neuron loss from spinal cord of quercetin-treated SMA mice at P10. (D) Untreated (left) and a quercetin-treated (right) SMA mice at P10. (E and F) Amelioration of skeletal muscle fibre atrophy in the levator auris longus (LAL) muscle of quercetin-treated SMA mice at P10 (n = 8 muscles Het, n = 9 KO, n = 4 KOQ). (G and H) Reduced NMJ pathology (average number of axonal inputs per NMJ; multiply innervated NMJs are indicated by arrows) in the LAL muscle of quercetin-treated SMA mice at P10 (n = 8 muscles Het, n = 9 KO, n = 4 KOQ). (I) Survival curve for quercetin-treated SMA mice showing no significant difference compared with DMSO-treated controls (P = 0.9897, χ² test; n = 10 mice DMSO; n = 13 quercetin). (J) Hearts (top) and livers (bottom) from control, SMA (KO DMSO), and quercetin-treated SMA (KO quercetin) mice at P10 showing no improvement in gross pathology. (K and L) UBA1 levels were reduced in all tissues from SMA mice at P10, but β-catenin levels were only correspondingly increased in spinal cord (n > 3 mice per genotype; ANOVA with Tukey's post-hoc). Scale bars: 200 μm (B), 25 μm (E and G), 5 mm (J). *P < 0.05; **P < 0.01; ***P < 0.001.
previously reported in zebrafish models of SMA (33). We identified β-catenin as a downstream target of UBA1/ubiquitination pathways in the neuromuscular system and showed a robust accumulation of β-catenin in SMA. Pharmacological inhibition of β-catenin signaling using quercetin ameliorated neuromuscular pathology caused by targeting of UBA1 and in zebrafish, Drosophila, and mouse models of SMA. Whereas disruption of UBA1 was found to occur across a range of neuronal and nonneuronal organs in SMA mice, surprisingly, we found that downstream disruption of β-catenin was restricted to the neuromuscular system and was not responsible for regulating SMN-dependent pathology in other tissues and organs. Our findings provide experimental evidence directly linking the regulation of ubiquitin homeostasis and β-catenin signaling to neuromuscular pathology in SMA and also reveal fundamental molecular differences between pathways underlying neuromuscular and systemic pathology in SMA.

Although it is known that SMN protein interacts with the ubiquitin-proteasome system in order to regulate its own stability (28–30), our study markedly extends our understanding of the importance of these interactions to include a direct role for dysregulation of ubiquitin homeostasis in the pathogenesis of SMA. When taken together with human genetic data showing that mutations in UBA1 cause pathological changes similar to those found in SMN-dependent SMA (22), our findings suggest that perturbations in ubiquitin homeostasis, and UBA1 in particular, may represent a common molecular pathway underlying neuromuscular pathology across genetically distinct forms of the disease. Moreover, the finding that perturbations in ubiquitin homeostasis in response to SMN deficiency as well as dysregulation of β-catenin downstream of perturbations in UBA1 are evolutionarily conserved among mouse, zebrafish and Drosophila models suggests that regulation of ubiquitin homeostasis represents a core response to low levels of functional SMN protein. Our finding that loss of UBA1 protein in SMA likely resulted from perturbations to both Uba1 mRNA missplicing and disruption to physical interactions between SMN and UBA1 as well as modifications to normal postnatal subcellular redistribution of the protein suggests that molecular pathways responsible for controlling UBA1 levels in vivo are complex and multifaceted. However, the demonstration of interactions between UBA1 and SMN provides additional evidence to support the hypothesis that interactions between SMN and ubiquitination pathways are key for the normal form and function of the neuromuscular system, not only with regards to the regulation of SMN protein stability (28–30), but also with respect to modulating ubiquitin homeostasis and cell viability.

Our identification of β-catenin as a key downstream target of ubiquitin pathways disrupted in SMA provides mechanistic insights into the pathways through which defects in ubiquitin homeostasis are transferred into pathological changes in the neuromuscular system. Although these pathways have not previously been linked to neuromuscular pathology in SMA, β-catenin signaling pathways are known to play an important role in regulating motor neuron differentiation and stability, including regulating synaptic structure and function (42–44). Interestingly, Li and colleagues previously reported that motor neuron differentiation is regulated by retrograde signaling through β-catenin from skeletal muscle (43). Our demonstration of robust amelioration of neuromuscular pathology in zebrafish, Drosophila, and mouse models of SMA treated with quercetin highlights the fact that β-catenin pathways in the neuromuscular system are amenable to pharmacological targeting in vivo. It should be noted, however, that quercetin is a pleiotropic flavonoid and as such is capable of modifying targets alongside β-catenin pathways. Nevertheless, targeting β-catenin signaling pathways (in addition to other pathways modulated by quercetin) during the early stages of disease may represent an attractive therapeutic option for stabilizing the neuromuscular system in SMA, and possibly also related conditions.

Given that β-catenin is such a well-established target for the ubiquitin-proteasome system and the magnitude of changes in β-catenin pathways observed in the neuromuscular system in SMA mice, it was surprising to find that quercetin treatment did not target systemic pathology in SMA. However, our finding that β-catenin signaling pathways remained stable in tissues and organs outside the neuromuscular system in SMA mice provides an explanation for this result and serves to highlight an underappreciated complexity in molecular pathways underlying disease pathogenesis in SMA. These findings also add further significant support to the hypothesis that SMA is a multisystem disorder (10) and add an additional layer of complexity with regards to distinct molecular pathways driving pathology in different tissues. Moreover, they further highlight the likely requirement to deliver therapeutics targeting either the SMN1 or SMN2 gene systemically in order to fully rescue SMA symptoms (14).

Methods

Mice, human patient samples, and study approvals. Severe (Snn+/− SMN2tg/0; ref. 45) and Taiwanese (Snn+/− SMN2tg/0; refs. 32, 46) SMA mice, both on a congenic FVB background, were obtained from Jackson Laboratories and maintained at the University of Edinburgh. Littermate animals either WT or heterozygous for Snn (Snn+/− or Snn+/−) were used for controls. Mice were bred and sacrificed under license from the United Kingdom Home Office, and were genotyped using standard PCR methods (5, 32).

Skeletal muscle (quadriiceps femoris) biopsy samples were obtained from 2 different biobanks in Italy (Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; Fondazione Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, IRCCS, Milan) through EuroBioBank (http://www.eurobiobank.org/). Biopsies were obtained from 3 type II/III SMA patients (aged between 3 and 25 years old), with a confirmed homozygous deletion in the SMN1 gene confirming a genetic diagnosis of SMA (47). Three age-matched control samples were also obtained; these were genetically confirmed to have no mutations in the SMN1 gene.

iTRAQ quantitative proteomics. iTRAQ proteomics was performed on freshly isolated synaptosome preparations from the hippocampus of P1 Snn+/− SMN2tg/0 (severe) and Snn+/− SMN2tg/0 (control) mice (n = 9 mice per genotype), as previously described (48). Samples were run in duplicate using the 4-plex system (114 and 116, SMA; 115 and 117, control). Only proteins identified by 2 or more unique peptides were taken forward for subsequent analysis. A stringent cut-off threshold of 20% change (increase or decrease) was used to identify proteins with modified expression. In silico functional pathways analyses were performed using Ingenuity Pathway Analysis software (48).

Western blot analyses. Quantitative Li-Cor fluorescent Western blotting was performed as previously described (4) using the following primary antibodies: SMN, synaptophysin (Santa Cruz Biotechnology Inc.); SMN, β-catenin (BD Biosciences); βIII tubulin, UBA1 (Abcam); histone H2B, active motif; Cox IV (MitoSciences); Ubiquitin (UBI1) (Millipore). Where required, 2 independent sets of measurements were produced per sample in order to minimize the effects of different laser scan intensities on the resulting data (e.g. where strong and weak bands were being measured on the same gel). Standard Western blotting was performed using the fol-
lowing primary antibodies: SMN: all MANSMA antibodies (49); gemin5: GEMS5M, GEMS5O, GEMS5Q. All protein levels reported on graphs represent arbitrary fluorescence units.

**IP experiments.** IP was performed as previously described (50). Briefly, protein was extracted in NP-40 lysis buffer (Novex; Life Technologies) containing 1% protease inhibitor cocktail (Roche). Following centrifugation at 16000 g, the supernatant was added to Dynabead protein G anti-mouse beads with preselected antibodies (β-catenin, UCHL1, and SMN) and subjected to quantitative fluorescent immunoblotting.

For Gemin5 IP experiments, anti-mouse Pan Ig-coated magnetic beads (50 μl) (Dynal) were washed in 4% BSA/PBS and incubated for 30 minutes with a monoclonal SMN antibody (10 μg; MANSMA12). GEMSM antibody against Gemin 5, or 150-kDa neurofilament antibodies as a control. After washing, beads were incubated with synaptosome extract for 1 hour, followed by washing 5 times with PBS. Proteins bound to beads were eluted by boiling in 2x SDS sample buffer, as previously described (51).

**RNA extraction, qPCR, and Uba1 splicing assays.** mRNA was extracted from synaptosomes using an RNasey Microkit (QIAGEN). Samples were checked for DNA contamination, and concentration was determined using a nanodrop spectrophotometer (Thermo Scientific) and using a standard PCR program with amplification following primers were used: Uba1 forward GGGCGGGGACTTTGTCTCTCT; Uba1 reverse CTTTGGACTGCTGAGCAAT; Fb1, forward AATCTTGGACCCACTGGTTCACCT; Fb1 reverse TCGAATCCGAGTAGTGGCATCAC; Mapt forward GCATTCTGGACTGAGCAGTTTACT; Mapt reverse TACGGACAAAGAAGCACCGGATC.

mRNA was extracted from spinal cord using an RNasey Microkit (QIAGEN). Samples were checked for DNA contamination, and concentration was determined using a nanodrop spectrophotometer (Thermo Scientific). RNA integrity was checked visually by resolution on agarose gels. cDNA was made from 2 μg mRNA using the High Capacity cDNA Reverse Transcription Kit (Invitrogen). Primers were designed that amplified the 2 mouse Uba1 transcripts, using a unique forward primer with a common reverse primer (Uba1a, forward GCTTTGGCTCCAGAAGGAGG; Uba1b, forward CTTGACCTGCGCTTTGAG; Uba1a/Uba1b, reverse CACTGAGGACACTTGAGCACA). Two mouse housekeeping genes (GAPDH and OAZ1) were used (GAPDH, forward CGTCCCGTAGACAAAATGGT; GAPDH, reverse TCGAATCCGAGTAGTGGCATCAC; Mapt, forward GCATTCTGGACTGAGCAGTTTACT; Mapt, reverse TACGGACAAAGAAGCACCGGATC).

**To examine levels of mono- and polyubiquitinated proteins in SMA skeletal muscle, we used wandering third instar larvae null for SMN (31). Ubiquitinated proteins were detected using an anti-mono- and polyubiquitylated primary antibody (1:100; FK2; BML-PWB110, Enzo Life Sciences). Nuclei were visualized using Hoechst (1:500). For the quercetin rescue experiments, SMN or WT flies (w118) were maintained on a diet of Drosophila Quick Mix Medium (Blades Biological) containing 8 to 50 μM quercetin hydrate (Sigma-Aldrich). Third instar smn null larvae were dissected and fixed. NMJ were visualized using Dylight 649–conjugated anti-HRP (1:200, Jackson ImmunoResearch), and the presynaptic marker cysteine string protein (1:200, Developmental Studies Hybridoma Bank) was used to identify synaptic boutons. The average number of boutons (normalized to muscle area) per NMJ at muscle 6/7 was calculated. Maximum bouton diameters were averaged per NMJ at muscle 6/7.

**UBEI-41 in vitro experiments.** Primary rat hippocampal cultures were established from E18 Sprague-Dawley rat embryos as previously described (52); NSC-34 cells (36) were generated from existing stocks held at the University of Edinburgh. UBEI-41 (Biogenova), a cell-permeable UBA1 inhibitor with an IC50 of approximately 5 μM, was added to the culture medium (50 μM) for 2 hours. β-catenin levels (and β-III tubulin loading control levels) were quantified using fluorescent Western blotting (see above) with anti-β-catenin (1:1000; BD Transduction Laboratories) and anti-β-III tubulin (1:1600; Abcam) primary antibodies.

To quantify β-catenin activity, NSC-34 cells were transiently transfected with a TOPflash reporter plasmid containing a luciferase reporter under the control of 3 copies of the TCF/LEF-binding element upstream of the thymidine kinase minimal reporter, specifically regulated by Wnt/β-catenin signaling. NSC-34 cells were seeded in a 24-well plate, and at 70%-80% confluency, cells were transfected, in triplicate, with 350 ng TOPflash plasmid using Lipofectamine 2000 (Invitrogen). To control for transfection efficiency, 20 ng phTKRenilla luciferase plasmid was used. Cells were treated with 50 μM UBEI-41 28 hours after transfection. Transfected samples were analyzed for firefly and Renilla luciferase activities 30 hours after transfection using the Dual-Luciferase Reporter Assay System (Promega) and measured using a FLUOstar OPTIMA Microplate Reader (BMG LABTECH). All values were corrected to blank wells and normalized to expression from the phTKRenilla plasmid.

**Zebrafish uba1 and smn knockdown.** An antisense MO was designed against the translational start codon of the uba1 gene (Gene Tools LLC): 5′-ACAGCGGCGGATGGGACAGTTCGAC-3′. The previously published smn-MO was designed against the 5′ start sequence of the smn gene (Gene Tools LLC): 5′-CGACATCTTTCTGACCAATGG-3′ (33). Zebrafish embryos were injected between the 1- and 4-cell stage. For direct evaluation of motor axon phenotype, we used embryos obtained from crossing TL/EK WT and Tg(mnx:GFP)ml2 transgenic animals (53). Embryos were injected with either 4 or 6 ng of uba1-MO or 4 ng of smn-MO in aqueous solution containing 0.05% phenol red and 0.05% rhodamine-dextran. Six hours after injection, embryos were sorted according to homogeneity of rhodamine fluorescence, reflecting equal distribution of the injected MO solution. Quercetin (Sigma-Aldrich) treatment was performed at 6 hpf. In brief, quercetin solution (in DMSO) or DMSO (Sigma-Aldrich) was added to buffered embryo medium (final volume: 2 μl as/os/ml medium) to obtain a final concentration of 50 μM. For immunostaining, Fish (34 hpf) were dechorionated and fixed in 4% PFA overnight, dehydrated in methanol, rehydrated, and washed in PBS. After collagenase treatment (1 μg/ml; C-9891, Sigma-Aldrich) for 10 minutes at room temperature, embryos were blocked in PBST plus 1% DMSO plus 10% FCS, followed by overnight incubation in 500 μl blocking solution containing monoclonal mouse anti-zebrafish Synaptotagmin (znp-1) antibody (1:300; Developmental Studies Hybridoma Bank). After washing, fish were incubated in donkey anti-mouse secondary antibody labeled with
Alexa Fluor 488 (1:200; Invitrogen). Microscopical analysis was performed in 80% glycerol on micro slides using an Axioskop 2 fluorescence microscope (Zeiss). The length of each of the first 10 motor axons behind the yolk was analyzed and evaluated, as was the extent of abnormal branching (Supplemental Figure 4).

Zebrafish UBE1–41 experiments. UBE1–41 (BioGenova), on its own or with quercetin (Sigma–Aldrich), was dissolved in DMSO and added at 6 hpf to Tg(mnx:GFP)222 embryos. The final amount of DMSO in the test groups was always 2 μl/ml in buffer embryo medium. Western blots were performed using the following antibodies: anti-β-actin (zebrafish) (rabbit polyclonal, 1:1,000; Anaspec); anti–UbA1 (mouse monoclonal, 1:1,000; Santa Cruz Biotechnology Inc.); anti–rabbit-HRP (1:10,000; GE Healthcare); anti–mouse-HRP (1:10,000; Sigma–Aldrich); anti–β-catenin (polyclonal rabbit, 1:1,000, C2206; Sigma–Aldrich). At 27 hpf, embryos were dechorionated, fixed in 4% PFA for 2 hours, and mounted in 70% glycerol. Motor nerves were assessed for abnormal trajectories using a Zeiss Axioscope A1 fluorescence microscope, and image stacks were taken using a Zeiss LSM710. For each embryo, 24 axons in 12 segments were analyzed. The observer was always blinded to the treatment.

SMA mouse quercetin experiments. Taiwanese mice and littermate controls were dosed daily with either 10 mg/kg quercetin (Sigma–Aldrich) or DMSO alone for a vehicle-only control via intraperitoneal injection. Mice were randomly assigned to treatment groups. Righting reflex tests were performed to assess neuromuscular function, as previously described (5). Muscle fibre diameter measurements were taken from phase-contrast micrographs of teased muscle fiber preparations using ImageJ software, as previously described (4). Motor neuron cell body counts were performed as previously described (32). NMJ pathology was assessed on whole-mount preparations of levator auris longus muscles, as described previously (5). Kaplan–Meier survival analyses were performed on DMSO and quercetin-treated mice as previously described (55). Organs were dissected and either fixed in 4% paraformaldehyde overnight for subsequent imaging, or were prepared for quantitative Western blotting.

Study approval. All required ethical approvals to acquire and distribute human patient tissue samples were obtained by the host biobanks. Tissue was provided in an anonymous fashion, with no identifying details apart from the age, sex, and genetic status of the patient. All animal studies were approved by the internal ethics committee at the University of Edinburgh and were performed under the authority of relevant project and personal licenses from the United Kingdom home office.

Statistics. All graphs are shown as mean ± SEM. All statistical analyses were completed using GraphPad Prism software. P < 0.05 was considered statistically significant for all analyses.

Acknowledgments

The authors are grateful to Nils Lindstrom and members of the Gillingwater laboratory for advice and assistance with this study and helpful comments on the manuscript; Neil Cashman for the NSC-34 cell line; and Ji-Long Liu for the Drosophila smn4 and smn9 lines. This work was supported by grants from the SMA Trust (to T.H. Gillingwater, P.J. Young, and R. Morse), BDF Newlife (to T.H. Gillingwater and S.H. Parson), the Anatomical Society (to T.H. Gillingwater and S.H. Parson), the Muscular Dystrophy Campaign (to T.H. Gillingwater), the Jennifer Trust for Spinal Muscular Atrophy (to H.R. Fuller), the Muscular Dystrophy Association (to G.E. Morris), the Vandervell Foundation (to P.J. Young), the Medical Research Council (GO82208 to I.M. Robinson), Roslin Institute Strategic Grant funding from the BBSRC (to T.M. Wishart), the BBiSRC (to C.G. Becker), the Deutsche Forschungsgemeinschaft and EU FP7/2007–2013 (grant no. 2012–305121, NeurOminics, to B. Wirth), the Center for Molecular Medicine Cologne (to B. Wirth and M. Hammerschmidt), and SMA Europe (to M.M. Reissland). We would also like to acknowledge financial support to the Gillingwater lab generated through donations to the SMASHSMA campaign.

Received for publication May 29, 2013, and accepted in revised form December 20, 2013.

Address correspondence to: Thomas H. Gillingwater, Euan Mac-Donald Centre for Motor Neurone Disease Research and Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, United Kingdom. Phone: 44.0.131.6503724; E-mail: T.Gillingwater@ed.ac.uk.